Ground-breaking new study shows the efficacy of a long-acting injectable to prevent HIV
GENEVA, 19 May 2020UNAIDS warmly welcomes the announcement that the long-acting injectable cabotegravir is safe and effective in preventing HIV among gay men and other men who have sex with men and transgender women. The HIV Prevention Trials Network (HPTN) 083 study enrolled almost 4600 HIV-negative people from across more than 40 sites in North and South America, Asia and Africa.
This is a breakthrough that will have a significant impact on the lives of gay men and other men who have sex with men and transgender women when they are at higher risk of HIV infection. said Shannon Hader, UNAIDS Deputy Executive Director, Programme. We are particularly pleased that the study met its targets to recruit substantial numbers of younger black men who have sex with men and transgender women, the very people for whom accessing effective HIV prevention still remains a huge challenge.
In 2018, UNAIDS estimates that there were 1.7 million new HIV infections, 54% of which were among key populations, including gay men and other men who have sex with men, transgender women, sex workers, people who inject drugs and people in prison.
Pre-exposure prophylaxis (PrEP)HIV-negative people using antiretroviral medicine to prevent HIV infectionis an important element in the HIV combination prevention toolkit. PrEP allows people to reduce their risk of becoming infected with HIV, particularly during periods of increased risk in their lives. It may also provide reassurance and reduce anxieties when the risks are uncertain.
Once it has passed regulatory approval, and when production of affordable cabotegravir can be scaled up, gay men and other men who have sex with men will have the choice of three highly effective ways to use PrEP to prevent HIV infection: daily pills, pills taken before and after sexual activity (event-driven PrEP) or an injection every two months. Transgender women will be able to choose between injections or daily pills, since the World Health Organization does not recommend event-driven PrEP because of possible drug interactions with some hormones. Injections of cabotegravir every two months are an important option for people who find it hard to take a pill every day, yet remain vulnerable to HIV infection.
The trial was scheduled to continue for at least another year, but the first interim analysis of the data was brought forward a few weeks because of the potential disruption that the COVID-19 pandemic might cause to high-quality clinical trial procedures. The Data and Safety Monitoring Board (DSMB) in the United States of America reviewed the data up to March 2020 and found that there was already clear evidence that cabotegravir was highly effective and not inferior to the currently recommended oral PrEP regimen.
Half of the study group were given oral PrEP and were injected with a placebo; the other half were given a cabotegravir injection and took a placebo pill. The study found a total of 12 HIV infections in the group using the injectable compared to 38 in the group taking the daily pill. The side-effects of both treatments were relatively mild, with only 2.2% of people in the injection group choosing to stop having the injections because of painful reactions. The DSMB therefore recommended that the study be halted and that all participants be notified of the result. The participants will be able to choose which regimen they wish to continue on.
Despite good adherence in the oral group and very few discontinuations in the injection group, the overall incidence of HIV infection in the study was 0.79 per 100 person-years. Planned analyses will explore why those 50 infections occurred among the 4565 trial participants.
An additional study (HPTN 084) is ongoing to establish the efficacy of the long-lasting injectable in non-transgender women. To date, more than 3000 sexually active women in seven African countries have enrolled in the study. Those results are expected in November.
We are eagerly awaiting the results of the ongoing HPTN 084 study among African women, said Dr Hader. We hope that by the end of this year there will be equally good news for women around the world.
HTPN 083 was conducted by the HPTN and funded by ViiV Healthcare and the United States National Institute of Allergy and Infectious Diseases. Cabotegravir has not yet been approved for the treatment or prevention of HIV as a single agent by regulatory authorities anywhere in the world. ViiV Healthcare plans to use the data from HPTN 083 for future regulatory submissions.
UNAIDS congratulates the research teams and urges continued investment in research and development for HIV vaccines, diagnostics, preventative medicines, treatment and a cure.
UNAIDS
The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizationsUNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bankand works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.
Originally posted here:
UNAIDS welcomes new tool for HIV prevention for gay men and other men who have sex with men and transgender women - UNAIDS
- Utilizing your free, preventative healthcare coverage - KELOLAND.com - February 18th, 2024
- Preventive Pros: the Podcast - Department of Population and Public Health Sciences - University of Southern California - February 18th, 2024
- Heart health awareness and preventative care with Jen Lewis on Coast Live - News 3 WTKR Norfolk - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - American Heart Association - February 18th, 2024
- Preventive health care benefits | Opinion | thecabin.net - Log Cabin Democrat - February 18th, 2024
- Menopause and migraines: New findings point to power of prevention - Medical Xpress - February 18th, 2024
- How Young Is Too Young For Preventative Skincare? Here's What Experts Want You To Know - Health.com - February 18th, 2024
- Potential prevention of rheumatoid arthritis with injection? Clinical study brings hope for millions - WION - February 18th, 2024
- Heart disease risk factors in women highlight need for increased awareness, prevention - Medical Xpress - February 18th, 2024
- Stay on top of your fur baby's health: the importance of scheduling routine vet visits - FoxReno.com - May 17th, 2023
- Preventive healthcare - May 9th, 2023
- What Is Preventive Health and Why Is It Important? - May 9th, 2023
- What Is Preventive Medicine & Why Do We Need It? | AUC - February 16th, 2023
- Preventive Medicine | Journal | ScienceDirect.com by Elsevier - December 3rd, 2022
- Migraine - Diagnosis and treatment - Mayo Clinic - December 3rd, 2022
- Functional Medicine of Idaho | Preventative Root Cause Medicine - December 3rd, 2022
- These 2 Staten Island nurses believe IV hydration drips and vitamin shots are key to long-term health - SILive.com - December 3rd, 2022
- CNBCTV-18 and IIM-K's India@2047 Leadership Series: Challenges and opportunities in the fintech and healthcare sectors - Forbes India - December 3rd, 2022
- As N.W.T. mulls health coverage changes, petition calls for preventative HIV drug to be free - CBC.ca - September 20th, 2022
- EU regulator backs wider use of AstraZeneca COVID therapy - Reuters - September 20th, 2022
- Choose integrative medicine for health and wellness - Technique - September 20th, 2022
- The high hospital bills we make victims of rape and sexual violence pay - Vox.com - September 20th, 2022
- 4 Anti-Aging Products Youre Using All Wrong, According To Skincare Experts - SheFinds - September 20th, 2022
- Why Now is the Time to Double Down on Virtual Care - HIT Consultant - September 20th, 2022
- Tell Giselle: The price of good help is priceless - Wilkes Barre Times-Leader - September 20th, 2022
- Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) - BioSpace - September 20th, 2022
- Pickleball injuries are on the rise: 5 preventive tips to keep you on the court - The Manual - September 20th, 2022
- The next big social movement and other takeaways from our regular meeting - POLITICO - September 20th, 2022
- 15 Mushrooms and How to Use Them in Vegan Cooking - VegNews - September 20th, 2022
- Use of honey in the management of Chemotherapy | CMAR - Dove Medical Press - September 20th, 2022
- Celebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - Forbes - September 20th, 2022
- C2C Care Course The Preservation of Our Global Photographic Heritage: Here, There and Everywhere - aam-us.org - August 3rd, 2022
- Loneliness: Causes, Effects And Prevention Forbes Health - Forbes - August 3rd, 2022
- Prevention and wellness is the new model, a leader from Henry Ford Health System says - Becker's Hospital Review - August 3rd, 2022
- FACT SHEET: White House Summit on Building Lasting Eviction Prevention Reform - The White House - August 3rd, 2022
- Getting Back to Employer Health and Wellness Programs - Cone Health - August 3rd, 2022
- Do ICDs Still Work in Primary Prevention Given Today's HF Meds? - Medscape - August 3rd, 2022
- Alzheimer's-defying brain offers clues to treatment, prevention - Harvard Gazette - August 3rd, 2022
- Wind-fanned lightning fire prompted precautionary evacuation notices near Medical Springs Sunday evening - Baker City Herald - August 3rd, 2022
- Experts discuss importance of cancer screenings and early detection - Merck - August 3rd, 2022
- King Institute of Preventive Medicine and Research to test samples for monkeypox - The Hindu - August 3rd, 2022
- Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations - World - ReliefWeb - August 3rd, 2022
- Dr. Sanjay Gupta: While monkeypox cases rise, why are we waiting for the cavalry to rescue us? - CNN - August 3rd, 2022
- SCYNEXIS Announces U.S. Food and Drug Administration - GlobeNewswire - August 3rd, 2022
- Governor Whitmer declares August 2022 as Breastfeeding Month, highlights additional breastfeeding observances - Michigan (.gov) - August 3rd, 2022
- New student education program supports drug and alcohol abuse prevention - The Ohio State University News - July 25th, 2022
- Suicide prevention training for health care providers a first step in longer-term efficacy - University of Washington - July 25th, 2022
- Pharmalittle: Congress may miss deadline to pass FDA user-fee bill; ViiV is urged to lower price for its HIV prevention drug - STAT - July 25th, 2022
- Prevention of Bipolar Disorder Episodes: Is It Possible? - PsychCentral.com - July 25th, 2022
- GAO Found Gap in Dirty Bomb Prevention - Government Technology - July 25th, 2022
- Florida man in apparent medical distress crashes car through beach crowd before hitting the water - CNN - July 25th, 2022
- Study: Preventive care scarce in LGBTQ+ community - - Medical Marketing and Media - July 25th, 2022
- The rise of preventive insurance purchases in India - ETHealthWorld - July 25th, 2022
- Why Are My Feet Always Cold? Cold Feet Causes and Treatment - Prevention Magazine - July 25th, 2022
- Agency looking to open overdose prevention site in Saint John amid 'poisoned' drug supply - CBC.ca - July 25th, 2022
- UVA Expert Offers Insight on the Use of Dietary Supplements for Cancer Prevention - UVA Today - July 25th, 2022
- Alzheimer's: Targeting key protein in blood may slow progression - Medical News Today - July 25th, 2022
- NPPC, FAS focused on ASF prevention in the Philippines - MEAT+POULTRY - July 25th, 2022
- Implementation of IPT in people living with HIV | RMHP - Dove Medical Press - July 25th, 2022
- NL starts preventive vaccination against monkeypox in Amsterdam, The Hague - NL Times - July 25th, 2022
- Precautionary measures you can take against brain haemorrhage - Times of India - July 25th, 2022
- Acid Reflux and Liver Disease: Signs, Symptoms and Prevention - Healthline - July 25th, 2022
- What to do if you get an allergic reaction: symptoms, causes, and prevention - Fox News - July 25th, 2022
- How one woman took control of her rare disease and achieved her dream - Times of Oman - July 25th, 2022
- Tilman Fertitta donating $50 million to UH medical school, which will be renamed after him - Houston Chronicle - May 20th, 2022
- This new 3D screensaver collection includes a driving tour of global pylons - Rock Paper Shotgun - May 20th, 2022
- Dedication, generosity and compassion that had no limit! - The Sun Chronicle - May 20th, 2022
- Manhattan internist and cardiologist, Dr. William Priester collaborates with Castle Connolly Private Health Partners to create a new concierge medical... - May 20th, 2022
- Tips on avoiding mosquitos this summer - morethanthecurve.com - May 20th, 2022
- Nanomedicine and HIV Therapeutics - AZoNano - May 20th, 2022
- The HIV Vaccine: What We Know, And What We Don't - MadameNoire - May 20th, 2022
- What we know (and don't know) about North Korea's COVID-19 outbreak - WCVB Boston - May 20th, 2022
- Experts warn of health effects from dusty conditions as sandstorm blankets UAE - Al Arabiya English - May 20th, 2022
- Statin therapy: Does the gut microbiome affect outcomes? - Medical News Today - May 20th, 2022
- New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News - November 7th, 2021
- MPD working with faith-based leaders to fight violent crime - FOX13 Memphis - November 7th, 2021
- Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com - November 7th, 2021
- Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner - November 7th, 2021
- Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie - November 7th, 2021
- The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News - November 7th, 2021